Literature DB >> 3487297

Predictors of mortality in the immunocompromised patient with pulmonary infiltrates.

R H Poe, G W Wahl, R Qazi, M C Kallay, M J Utell, G R Morrow.   

Abstract

To determine predictors of mortality in immunocompromised patients with pulmonary infiltrates, we reviewed the records of all such patients admitted to two community teaching hospitals who underwent a lung biopsy over a ten-year period. We examined the consequences of advancing age, primary disease, fever, neutropenia, immunosuppressive corticosteroid therapy, previous lung radiation, roentgenographic pattern, result of lung biopsy, room air arterial oxygen pressure (Pao2), early mechanical ventilation, and the presence of a comorbid disease on eventual outcome. We identified 104 episodes in 99 patients. Sixty-seven (64%) survived and 37 died. By both discriminant analysis and logistic regression statistical methods, mechanical ventilation, the initial room air Pao2, and corticosteroid therapy were the dominant independent variables, in that order, to significantly predict mortality. No patient survived who simultaneously had a room air Pao2 less than or equal to 50 mm Hg, was on corticosteroids, and was mechanically ventilated. Eighty-three percent of survivors had either none or, at most, one of these three variables present. We conclude that hypoxia, immunosuppression by corticosteroids, and the necessity for mechanical ventilation within 72 hours of hospitalization indicate a poor prognosis in the immunocompromised patient with pulmonary infiltrates who has undergone a lung biopsy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487297

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Quality of published reports of the prognosis of community-acquired pneumonia.

Authors:  C A Carson; M J Fine; M A Smith; L A Weissfeld; J T Huber; W N Kapoor
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 3.  The pulmonary physician in critical care. Illustrative case 2: interstitial lung disease.

Authors:  A T Jones; R M du Bois; A U Wells
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

4.  Outcome of ICU treatment in invasive aspergillosis.

Authors:  J J Janssen; R J Strack van Schijndel; E H van der Poest Clement; G J Ossenkoppele; L G Thijs; P C Huijgens
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

5.  Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients.

Authors:  C Agustí; A Rañó; M Rovira; X Filella; N Benito; A Moreno; A Torres
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

6.  Open lung biopsy in early-stage acute respiratory distress syndrome.

Authors:  Kuo-Chin Kao; Ying-Huang Tsai; Yao-Kuang Wu; Ning-Hung Chen; Meng-Jer Hsieh; Shiu-Feng Huang; Chung-Chi Huang
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors.

Authors:  Nathalie Dartois; C Angel Cooper; Nathalie Castaing; Hassan Gandjini; Denise Sarkozy
Journal:  Open Respir Med J       Date:  2013-02-22

8.  Usefulness of open lung biopsy in mechanically ventilated patients with undiagnosed diffuse pulmonary infiltrates: influence of comorbidities and organ dysfunction.

Authors:  Seong Yong Lim; Gee Young Suh; Jae Chol Choi; Won Jung Koh; Si Young Lim; Joungho Han; Kyung Soo Lee; Young Mog Shim; Man Pyo Chung; Hojoong Kim; O Jung Kwon
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.